The effect of high-dose saquinavir on viral load and CD4+ t-cell counts in HIV-infected patients

Annals of Internal Medicine

Volumn 124, Issue 12, 1996, Pages 1039-1050

  Schapiro, Jonathan M ^b   Winters, Mark A ^b   Stewart, Fran ^c   Efron, Bradley ^a   Norris, Jane ^b   Kozal, Michael J ^d   Merigan, Thomas C ^a  

^a STANFORD UNIVERSITY   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c ROCHE PRODUCTS LTD   (United Kingdom)

^d UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE; ANTIGEN P24; ANTIRETROVIRUS AGENT; CD4 ANTIGEN; SAQUINAVIR; VIRUS RNA; ZIDOVUDINE;

ADULT; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; DIARRHEA; DRUG EFFECT; DRUG MEGADOSE; DRUG SAFETY; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MALE; MONONUCLEAR CELL; NAUSEA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; VERTIGO; VIRUS LOAD;

ADULT; BASE SEQUENCE; CD4 LYMPHOCYTE COUNT; DNA PRIMERS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HIV CORE PROTEIN P24; HIV INFECTIONS; HIV PROTEASE; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; ISOQUINOLINES; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; MUTATION; QUINOLINES; RNA, VIRAL; SAQUINAVIR; VIREMIA;

EID: 0030317870     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-124-12-199606150-00003     Document Type: Article

References (41)

1. Meek TD, Lambert DM, Dreyer GB, Carr TJ, Tomaszek TA Jr, Moore ML, et al. Inhibition of HIV-1 protease in infected T-lymphocytes by synthetic peptide analogues. Nature. 1990;343:90-2.
2. McQuade TJ, Tomasselli AG, Liu L Karacostas V, Moss B, Sawyer TK, et al. A synthetic HIV-1 protease inhibitor with antiviral activity arrests HIV-Itke particle maturation. Science. 1990;247:454-6.
3. Lambert DM, Petteway SR Jr, McDanal CE, Hart TK, Leary JJ, Dreyer GB, et al. Human immunodefiency virus type 1 protease inhibitors irreversibly block infectivity of purified virions from chronically infected cells. Antimicrob Agents Chemother. 1992;36:982-8
4. Roberts NA, Martin JA, Kinchington D, Broadhurst AV, Craig JC, Duncan IB, et al. Rational design of peptide-based HIV proteinase inhibitors. Science. 1990;248:358-61.
5. Craig JC, Duncan IB, Hockley D, Grief C, Roberts NA, Mills JS. Antiviral properties of Ro 31-8959, an inhibitor of human immunodefiency virus (HIV) proteinase. Antiviral Res. 1991;16:295-305.
6. Martin JA, Mobberley MA, Redshaw S, Burke A, Tyms AS, Ryder TA. The inhibitory activity of a peptide derivative against the growth of simian immunodefiency virus in C8166 cells. Biochem Biophys Res Commun. 1991;176:180-8.
7. Kitchen VS, Skinner C, Ariyoshi K, Lane EA, Duncan IB, Burckhardt J, et al. Safety and activity of saquinavir in HIV infection. Lancet. 1996;345:952-5.
8. Williams PE, Madigen MJ, Mitchel AM. A single dose, randomized crossover study of the absolute and relative bioavailabilty of Ro 31-8959 in healthy volunteers. Roche Reasearch Report. 1992 No. W-141[prime]786.
9. Markowitz M, Mo H, Kempf DJ, Norbeck DW, Bhat TN, Erickson JW, et al. Selection and analysis of human immunodefiency virus type 1 variants with increased resistance to ABT-538, a novel protease inhibitor. J Virol 1995;69:701-6.
10. Kaplan AH, Michael SF, Wehbie RS, Knigge MF, Paul DA, Everitt L, et al. Selection of multiple human immunodefiency virus type 1 variants that encode viral proteases with decreased sensitivity to an inhibitor of the viral protease Proc Natl Acad Sci U S A. 1994;91:5597-601.
11. Patick AK, Rose R, Greytok J, Bechtold CM, Hermsmeier MA, Chen PT, et al. Characterization of a human immunodefiency virus type 1 variant with reduced sensitivity to an aminodiol protease inhibitor. J Virol. 1995;69:2148-52.
12. Ho DD, Toyoshima T, Mo H, Kempf DJ, Norbeck D, Chen CM, et al. Characterization of human immunodefiency virus type 1 variants with increased resistance to a C2-symmetric protease inhibitor. J Virol. 1994;68:2016-20.
13. King RW, Garber S, Winslow DL, Reid C Bacheler LT, Anton E, et al. Multiple mutations in the human immunodefiency virus protease gene are responsible for decreased susceptibility to protease inhibitors. Antiviral Chem Chemother. 1995;6:80-8.
14. Turriziani O, Antonelli G, Jacobsen H, Mous J, Riva E, Pistello M, et al. Identification of an amino acid subsitutuion involved in the reduction of sensitivity of HIV-1 to an inhibitor of viral proteinase. Acta Virol. 1994;38:297-8.
15. Jacobsen H, Yasargil K, Winslow DU Craig JC, Krohn A, Duncan IB, et al. Characterization of human immunodefiency virus type 1 mutants with decreased sensitivity to proteinase inhibitor Ro 31-8959. Virology. 1995;206:527-34.
16. Maschera B, Furfine E, Blair ED. Analysis of resistance to human immunodefiency virus type 1 protease inhibitors by using matched bacterial expression and proviral infection vectors. J Virol. 1995;69:5431-6.
17. Eberle J, Bechowsky B, Rose D, Hauser U, von der Helm K, Gurtler L, et al. Resistance of HIV type 1 to protease inhibitor Ro 31-8959. AIDS Res Hum Retroviruses. 1995;11:671-6.
18. Molla A, Boucher C, Korneyeva M, Gao Q, Schipper P, Lyons N, et al. Evolution of resistance to the protease inhibitor ritonavir (ABT-538) in HIV infected patients [Abstract]. Fourth International Workshop on HIV Drug Resistance, Sardinia, 6-9 July 1995.
19. Mellors JW, McMahon DK, Chodakewitz JA, Schleif WA, Emini EA, Condra JH, et al. Correlation between genotypic evidence of HIV-1 resistance to the protease inhibitor MK-639 and loss of antiretroviral effect in treated patients [Abstract], Fourth International Workshop on HIV Drug Resistance, Sardinia, 6-9 July 1995
20. Condra JH, Schleif WA, Blahy OM, Gabryelski U, Graham DJ, Quintero JC, et al. In vivo emergence of HIV-1 varients resistant to multiple protease inhibitors. Nature. 1995;374:569-71.
21. Tisdale M, Myers RE, Maschera B, Parry NR, Oliver NM, Blair ED. Cross-resistance analysis of human immunodefiency virus type 1 variants individually selected for resistance to five different protease inhibitors. Antimicrob Agents Chemother. 1995;39:1704-10.
22. Roberts NA, Race E, Tomlinson P, Gilbert S, Duncan IB. Resistance and cross resistance issues: studies with saquinavir (Abstract). In: Program and Abstracts-35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, 17-20 September 1995. Washington, DC: American Society for Microbiology: 1995.
23. Collier AC, Coombs RW, Schoenfeld DA, Bassett R, Baruch A, Corey L. Extended treatment with Saquinavir (SAQ), Zidovudme (ZDV) and Zalcitabine (ddC) vs. SAO and ZDV vs. ddC and ZDV [Abstract]. In: Program and Abstracts-35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, 17-20 September 1995. Washington, DC: American Society for Microbiology: 1995.
24. Hollinger FB, Bremer JW, Myers LE, Gold JW, McQuay L Standardization of sensitive human immunodefiency virus coculture procedures and establishment of a multicenter quality assurance program for the AIDS clinical trials group. The NIH/NIAID/DAIDS/ACTG Virology Laboratories. J Clin Microbiol. 1992;30:1787-94.
25. Winters MA, Tan LB, Katzenstein DA, Merigan TC. Biological variation and quality control of plasma human immunodefiency virus type 1 RNA quantitation by reverse transcriptase polymerase chain reaction. J Clin Microbiol. 199;31:2960-6.
26. Lin HJ, Myers LE, Yen-Lieberman B, Hollinger FB, Henrard D, Hooper CJ, et al. Multicenter evaluation of quantification methods for plasma human immunodefiency virus type 1 RNA, J Infect Dis. 1994;170:553-62.
27. Wood R, Dong H, Katzenstein DA, Merigan TC. Qualification and comparison of HIV-1 proviral load in peripheral blood mononuclear cells and isolated CD4 + T cells. J Acquir Immune Defic Syndr. 1993;6:237-40.
28. Larder BA, Kellam P, Kemp SD. Zidovudine resistance predicted by direct detection of mutations in DMA from HIV-infected lymphocytes. AIDS. 1991;5:137-44.
29. Kozal MJ, Shafer RW, Winters MA, Katzenstein DA, Merigan TC. A mutation in human immunodefiency virus reverse transcriptase and decline in CD4 lymphocyte numbers in long-term Zidovudine recipients. J Infect Dis. 1993;167:526-32.
30. Boucher CA, Tersmette M, Lange JM, Kellam P, de Goede RE, Mulder JW, et al. Zidovudine sensitivity of human immunodefiency viruses from high-risk, symptom-free individuals during therapy. Lancet. 1990;336:585-90.
31. Boucher CA, O'Sullivan E, Mulder JW, Ramautarsing C, Kellam P, Darby G, et al. Ordered appearence of Zidovudine resistance mutations during treatment of 18 human immunodefiency virus-positive subjects. J Infect Dis. 1992;165:105-10.
32. Danner SA, Carr A, Leonard JM, Lehman LM, Gudiol F, Gonzales J, et al. A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. European-Australian Collaborative Ritonavir Study Group. N Engl J Med. 1995;333:1528-33.
33. Markowitz M, Saag M, Powderly WG, Hurley AM, Hsu A, Valdes JM, et al. A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. N Engl J Med. 1995;333:1534-9.
34. Fischl MA, Richman DD, Hansen N, Collier AC, Carey JT, Para MF, et al. The safety and efficacy of Zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodefiency virus type I (HIV) infection. A double-blind, placebo-controlled trial. The AIDS Clinical Trials Group. Ann Intern Med. 1990;112:727-37.
35. Yardioan R, Pluda JM, Thomas RV, Mitsuya H, Brouwers P, Wyvill KM, et al. Long term toxicity/activity profile of 2′,3′-dideoxyinosine in AIDS or AIDS related complex. Lancet. 1990;336:526-9.
36. Merigan TC, Skowron G. Safety and tolerence of dideoxycytidine as a single agent. Results of early-phase studies in patients with acquired immunodeficiency syndrome (AIDS) or advanced AIDS-related complex. Study Group of the AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases. Am J Med. 1990;88:11S-15S.
37. Kozal MI, Shafer RW, Winters MA, Katzenstein DA, Merigan TC. A mutation in human immunodefiency virus reverse transcriptase and decline in CD4 lymphocyte numbers in long-term zidovudine recipients. J Infect Dis. 1993;167:526-32.
38. Richman DD, Grimes JM, Lagakos SW. Effect of stage of disease and drug dose on zidovudine susceptibilities of isolates of human immunodefiency virus. J Acquir Immune Defic Syndr. 1990;3:743-6.
39. Kozal MJ, Kroodsma K, Winters MA, Shafer RW, Efron B, Katzenstein DA, et al. Didanosine resistance in HlV-infected patients switched from zidovudine to didanosine monotherapy. Ann Intern Med. 1994;121:263-8.
40. Shafer RW, Kozal MJ, Winters MA, Iversen AK, Katzenstein DA. Ragni MV, et al. Combination therapy with zidovudine and didanosine selects for drug-resistant human immunodefiency virus type 1 strains with unique patterns of pol gene resistance. J Infect Dis. 1994;169:722-9.
41. Larder BA, Kemp SD, Harrigan PR. Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science. 1995;269:696-9.